Replay launches gene therapy spinout Eudora, putting ‘hub-and-spoke’ plans to work
Eudora will use Replay’s viral vector delivery technology to develop treatments for diseases of the eye.
Replay, a biotechnology startup built around several gene therapy technologies, has launched the first of several planned spinouts, revealing on Monday a company named Eudora. The company follows what it terms a “hub-and-spoke” model, aiming to share its technology across several companies, each working on a specific therapeutic area.
Eudora will focus on eye diseases, initially Stargardt disease, retinitis pigmentosa and Usher syndrome type 1B.
Replay, and now Eudora, envision the HSV viral vector as an alternative to the adeno-associated virus, or AAV, that’s typically used in gene therapy. While AAV vectors are limited in how much genetic material they can carry, Replay claims its HSV platform can deliver “eight times” the genetic payload of AAV vectors.
Replay said it is developing another HSV vector that could deliver up to 30 times the payload that AAV vectors can.
Three other, as-yet-unnamed Replay companies will use the HSV vector to develop treatments for monogenic diseases of the brain, skin, and muscle, Replay said.
https://www.biopharmadive.com/news/replay-eudora-spinout-gene
ارسال به دوستان